Select Your Region
Global
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
- Solid Tumors
Trial Status:
Recruiting
This trial runs in
Cities
- Adana
- Ankara
- Asvestochori
- Athens
- bad-saarow
- Bayrut
- Bengaluru
- Beograd
- Besançon
- Bogotá
- Bratislavský kraj
- Brest
- Buenos Aires
- Calgary
- Cali
- Cebu City
- Chennai
- Ciudad de México
- Dublin 24
- Dublin 8
- Edirne
- Golnik
- Halle (Saale)
- Hannover
- Hanoi
- Heilbronn
- heroica-puebla-de-zaragoza
- Hyderabad
- İstanbul
- Jerusalem
- Johannesburg
- Kaohsiung City
- Krung Thep Maha Nakhon
- Las Condes
- Levallois-Perret
- Lille
- Medellín
- Mumbai
- Ottawa
- Palma
- Pamplona
- Paris
- Pireas
- Porto
- Pretoria
- Quimper
- Rennes
- Rio Grande do Sul
- Riyadh
- Saint-Priest-en-Jarez
- Saint-Étienne
- Santiago
- Sremska Kamenica
- Stuttgart
- São Paulo
- Taipei City
- Tallinn
- Taoyuan City
- Tartu
- Tel Aviv-Yafo
- Thessaloniki
- Thành phố Hồ Chí Minh
- Villejuif
- Warszawa
- Wesel
- Zaragoza
- دبي
Trial Identifier:
NCT04529122 MX39897
Trial Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Hoffmann-La Roche
Sponsor
NCT04529122 , MX39897
Trial Identifier
Solid Tumours
Condition
Official Title
A Registry to Collect the Natural History of Solid Tumour Cancers in Patients Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Exclusion Criteria
- Participant has a prior or current diagnosis of haematological malignancy
For the latest version of this information please go to www.forpatients.roche.com